1	Are female-specific cancers long-term sequelae of COVID-19? Evidence from a large-
2	scale genome-wide cross-trait analysis
3	Xunying Zhao ^{1¶} , Xueyao Wu ^{1¶} , Jinyu Xiao ¹ , Li Zhang ¹ , Yu Hao ¹ , Chenghan Xiao ² , Ben
4	Zhang ¹ *, Jiayuan Li ¹ *, Xia Jiang ^{1,3,4,5} *
5	¶ Xunying Zhao and Xueyao Wu contributed equally to this work.
6	Affiliations:
7	¹ Department of Epidemiology and Biostatistics and West China-PUMC C. C. Chen Institute of
8	Health, West China School of Public Health and West China Fourth Hospital, Sichuan
9	University, Chengdu, Sichuan, China.
10	² Department of Maternal, Child and Adolescent Health, West China School of Public Health
11	and West China Fourth Hospital, Sichuan University, Chengdu, China.
12	³ Department of Nutrition and Food Hygiene, West China School of Public Health and West
13	China Fourth Hospital, Sichuan University, Chengdu, China
14	⁴ Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet,
15	Solna, Stockholm, Sweden.
16	⁵ Program in Genetic Epidemiology and Statistical Genetics, Harvard T. H. Chan School of
17	Public Health, Boston, Massachusetts, USA.
18	
19	*Correspondence to: West China School of Public Health and West China Fourth Hospital,
20	Sichuan University 16#, Section 3, Renmin Nan Lu Chengdu, Sichuan 610041, P. R. China
21	(Ben Zhang, PhD, E-mail: <u>ben.zhang@scu.edu.cn</u> ; Jiayuan Li, PhD, E-mail:
22	lijiayuan@scu.edu.cn; Xia Jiang, PhD, E-mail: xiajiang@scu.edu.cn).
23	Word Count: 4,526
24	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 ABSTRACT

Background: Little is known regarding the long-term adverse effects of COVID-19 on femalespecific cancers due to the restricted length of observational time, nor the shared genetic
influences underlying these conditions.

Methods: Leveraging summary statistics from the hitherto largest genome-wide association studies conducted in each trait, we performed a comprehensive genome-wide cross-trait analysis to investigate the shared genetic architecture and the putative genetic associations between COVID-19 with three main female-specific cancers: breast cancer (BC), epithelial ovarian cancer (EOC), and endometrial cancer (EC). Three phenotypes were selected to represent COVID-19 susceptibility (SARS-CoV-2 infection) and severity (COVID-19 hospitalization, COVID-19 critical illness).

Results: For COVID-19 susceptibility, we found no evidence of a genetic correlation with any 36 of the female-specific cancers. For COVID-19 severity, we identified a significant genome-37 wide genetic correlation with EC for both hospitalization ($r_q=0.19$, P=0.01) and critical illness 38 $(r_g = 0.29, P = 3.00 \times 10^{-4})$. Mendelian randomization demonstrated no valid association of 39 40 COVID-19 with any cancer of interest, except for suggestive associations of genetically predicted hospitalization (OR_{IVW}=1.09, 95%CI=1.01-1.18, P=0.04) and critical illness 41 (OR_{IVW}=1.06, 95%CI=1.00-1.11, P=0.04) with EC risk, none withstanding multiple correction. 42 No reverse association was found. Cross-trait meta-analysis identified multiple pleiotropic 43 44 SNPs between COVID-19 and female-specific cancers, including 20 for BC, 15 for EOC, and 45 5 for EC. Transcriptome-wide association studies revealed shared genes, mostly enriched in the 46 hematologic, cardiovascular, and nervous systems.

47 **Conclusions:** Our genetic analysis highlights an intrinsic link underlying female-specific 48 cancers and COVID-19 - while COVID-19 is not likely to elevate the immediate risk of the 49 examined female-specific cancers, it appears to share mechanistic pathways with these 50 conditions. These findings may provide implications for future therapeutic strategies and public

51 health actions.

- 52 Keywords: COVID-19, SRAS-CoV-2, female-specific cancer, pleiotropic loci, Mendelian
- 53 randomization, genetic correlation

54 Introduction

55 With more than half a billion registered infections and 6.4 million deaths globally, the coronavirus disease 2019 (COVID-19) continues to spread (WHO: https://covid19.who.int/). 56 57 Despite lungs being the organ predominately affected, a multi-system involvement of COVID-19 is well-characterized, with extra-pneumatic manifestations documented in hematologic, 58 cardiovascular, neurological tissues, and others, possibly caused by direct viral virulence or as 59 a result of immunopathological reactions^{1,2}. Moreover, while most COVID-19 patients recover 60 within a couple of weeks after infection, a non-negligible proportion of individuals experience 61 chronic symptoms lasting for months, especially in women^{3,4}. Given the extensive and likely 62 prolonged impairment of COVID-19 on multiple bodily systems, its long-term sequelae have 63 become increasingly recognized and concerning^{3,5}. 64

Strong evidence has been raised reflecting the disparities in COVID-19 pandemic, potentially 65 mediated through unique social determinants of health^{6,7}. Women, especially those with high 66 health burdens are affected disproportionally by COVID-19^{6,8}. For example, individuals with 67 breast cancer (BC) were nearly 3-times more likely to die from COVID-19 than their non-68 cancer referents (odds ratio, OR = 3.30; 95% confidence interval, 95% CI = 1.96-5.57)⁹. Among 69 70 women with gynecological cancers, mainly epithelial ovarian cancer (EOC) and endometrial cancer (EC), a significantly increased mortality due to COVID-19 (14.0%)¹⁰ was found 71 compared to general population (5.6%)¹¹. Indeed, several shared signaling pathways, including 72 cytokine, immunosuppression, coagulation disorders, inflammatory reactions, and hormone 73 secretion¹²⁻¹⁵, have been reported. Nevertheless, whether COVID-19 increases the susceptibility 74 75 to cancer in those without prior malignancies remains unclear due to the hitherto restricted length of observational time. It is concerned that COVID-19 may predispose recovered patients 76 to cancer development based on the growing evidence of SARS-CoV-2 in modulating 77 78 oncogenic pathways, promoting chronic low-grade inflammation, and causing tissue damage^{12,16}. 79

80 One way of evaluating the putative causal association underlying two phenotypes is to apply

Mendelian randomization (MR)¹⁷, a framework leveraging genetic variants as instruments to 81 82 overcome the limitation of conventional epidemiological designs, such as restricted observational duration, environmental confounder, and reverse association¹⁸. Using other 83 genetic methods including genetic correlation analysis¹⁹, cross-trait meta-analysis²⁰, and 84 transcriptome-wide association study (TWAS)²¹, shared genetic influences across traits can also 85 be quantified, driving forward epidemiologic associations with novel insights into the 86 underlying biological mechanisms. Here, we apply these methods to perform a comprehensive 87 genome-wide cross-trait analysis¹⁸, with an overarching goal of characterizing the shared 88 89 genetic architecture and the putative associations underpinning COVID-19 and female-specific cancers (BC, EOC, and EC). Three COVID-19 phenotypes were included, namely SARS-CoV-90 91 2 infection, COVID-19 hospitalization, and COVID-19 critical illness. The overview of study 92 design is shown in Fig 1.

93

94 Materials and methods

95 GWAS data sets

Cancer Three common female malignant tumors, the breast cancer (BC), the epithelial ovarian 96 cancer (EOC), and the endometrial cancer (EC)²², were included in our study. GWAS summary 97 98 data of BC was obtained from a meta-analysis of the Breast Cancer Association Consortium (BCAC) and 11 other BC genetic studies²³, involving 133,384 cases and 113,789 controls. 99 GWAS summary data of overall invasive EOC was obtained from the Ovarian Cancer 100 Association Consortium (OCAC) meta-analysis²⁴, involving 22,406 cases and 40,941 controls. 101 102 GWAS summary data of EC was obtained from a meta-analysis of the Endometrial Cancer 103 Association Consortium (ECAC), the Epidemiology of Endometrial Cancer Consortium (E2C2), and the UK Biobank²⁵, involving 12,906 cases and 108,979 controls. All individuals 104 105 were of European ancestry.



107 European ancestry conducted by the COVID-19 Host Genetics Initiative, release 7 (https://www.covid19hg.org/), from which subjects of 23andMe were excluded due to data 108 restrictions²⁶. Three phenotypes were selected and further divided into two categories, 109 representing COVID-19 susceptibility and severity. SARS-CoV-2 infection, defined as "cases 110 111 with reported SARS-CoV-2 infection regardless of symptoms (N = 122,616) vs. population (N = 2,475,240)", was used to index COVID-19 susceptibility. COVID-19 hospitalization, 112 113 defined as "moderate or severe COVID-19 patients who were hospitalized due to COVID-19 114 symptoms (N = 32,519) vs. population (N = 2,062,805)", and COVID-19 critical illness, 115 defined as "severe COVID-19 patients who needed respiratory support or who died due to the 116 disease (N = 13,769) vs. population (N = 1,072,442)" were used to index COVID-19 severity. 117 Considering a potential sample overlap between GWAS of EC and GWAS of COVID-19 phenotypes (both involving UK Biobank subjects), we further performed a sensitivity analysis 118 119 using trans-ancestry COVID-19 GWAS excluding individuals of UKB. Details on the 120 characteristics of each included dataset are presented in Supplementary Table 1.

121 Statistical analysis

122 Genome-wide genetic correlation analysis To describe the average shared genetic effect between female-specific cancers and COVID-19 phenotypes, we quantified their genome-wide 123 genetic correlation using pairwise linkage-disequilibrium score regression (LDSC)¹⁹. The 124 125 genetic correlation estimates r_q range from -1 to +1, with +1 indicating a complete positive 126 correlation and -1 indicating a complete negative correlation. We used pre-computed LD-127 scores obtained from ~ 1.2 million common SNPs of European ancestry represented in the Hapmap3 reference panel. Bonferroni correction was applied to account for multiple testing. 128 We defined a significant r_a as $P < 5.56 \times 10^{-3}$ ($\alpha = 0.05/9$, number of phenotype pairs)²⁷, and 129 suggestive r_q as $5.56 \times 10^{-3} \le P < 0.05$. 130

Bidirectional Mendelian randomization analysis The average shared genetic effects can be decomposed into vertical pleiotropy and/or horizontal pleiotropy, where vertical pleiotropy (or a putative causal association) refers to genetic variants affecting one trait (outcome) via its

134 effect on an intermediate trait (exposure), and horizontal pleiotropy, often simplified as pleiotropy, refers to genetic variants affecting both traits independently¹⁸. To further explore 135 these alternatives, we first conducted a bidirectional two-sample MR between COVID-19 136 phenotypes and female-specific cancers. As no significant SNP was reported in the original 137 COVID-19 GWAS, we selected independent instrumental variables (IVs) by clumping all 138 variants that reached genome-wide significance ($P \le 5 \times 10^{-8}$) according to a strict criterion ($r^2 \le$ 139 0.001 within a 1.0Mb window). For cancers, we collected all previously reported independent 140 index SNPs reaching genome-wide significance ($P < 5 \times 10^{-8}$) from corresponding GWAS. We 141 142 calculated the F-statistic to evaluate instrument strength, with an F-statistic < 10 indicating a weak instrument²⁸. 143

We applied inverse-variance weighted (IVW) method as our primary approach¹⁷, complemented with MR-Egger²⁹ and weighted median³⁰ to evaluate its robustness. A Bonferroni-corrected significance threshold of $P < 5.56 \times 10^{-3}$ ($\alpha = 0.05/9$, number of phenotype pairs) was applied²⁷, while $5.56 \times 10^{-3} \le P < 0.05$ was defined as suggestive significance. An MR effect estimate was considered robust if it was statistically significant in IVW and remained directionally consistent across both the MR-Egger and the weighted median approaches.

To validate MR model assumptions, we conducted several important sensitivity analyses. First, we excluded palindromic IVs that have the same alleles on forward and reverse strands, and pleiotropic IVs that are associated with potential confounders according to GWAS catalog (<u>https://www.ebi.ac.uk/gwas/</u>, accessed on 05/08/2021). Next, we performed a leave-one-out analysis in which we excluded one IV at a time and conducted IVW using the remaining SNPs to identify outlying instruments. Finally, we used MR-Pleiotropy Residual Sum and Outlier (MR-PRESSO) approach to detect and correct for horizontal pleiotropy³¹.

157 **Cross-trait meta-analysis** To identify pleiotropic loci affecting both traits, we further 158 performed a cross-trait meta-analysis using Cross Phenotype Association (CPASSOC)²⁰. We 159 chose S_{Het} , a statistic that is more powerful for heterogonous effects (common when meta-160 analysing different traits), to combine summary statistics across traits. We used PLINK 1.9

161 "clumping" function to obtain independent loci with parameters: --clump-p1 5e-8 --clump-p2 1e-5 --clump-r2 0.2 --clump-kb 500³². Index SNPs, satisfying $P_{\text{CAPSSOC}} < 5 \times 10^{-8}$ and $P_{\text{single-trait}} <$ 162 1×10^{-3} (both traits), were considered as significant pleiotropic SNPs. An index SNP satisfying 163 the following conditions was considered as a novel shared SNP: (1) did not reach genome-wide 164 165 significance $(5 \times 10^{-8} < P_{\text{single-trait}} < 1 \times 10^{-3})$ in single-trait GWAS; and (2) was not in LD ($r^2 < 0.05$) with any of the previously reported genome-wide significant SNPs in single-trait GWAS. To 166 167 further investigate biological insights for the shared variants, we use Ensemble Variant Effect 168 Predictor (VEP) to annotate the linear closest genes of the identified pleiotropic SNPs³³.

Fine-mapping credible set and colocalization analysis Due to the complex LD patterns among SNPs, index SNPs are not necessarily causal variations³⁴. We conducted a fine-mapping analysis using FM-summary to identify a credible set of variants that were 99% likely to contain causal variants at each of the shared loci. FM-summary is a fine-mapping algorithm in Bayesian framework which maps the primary signal and uses a flat prior with steepest descent approximation³⁵.

To assess whether the same variants are responsible for two GWAS signals or are distinct variants close to each other, we conducted a colocalization analysis using Coloc³⁶. Coloc is a tool in Bayesian framework that provides intuitive posterior probabilities of 5 hypotheses (H0-H4). We extracted summary statistics for variants within 500 kb of each shared index SNP and calculated the posterior probability for H4 (PPH4, the probability that both traits are associated through sharing a single causal variant). A locus was considered colocalized if PPH4 was greater than 0.5.

Transcriptome-wide association studies Many genetic variants implement their function by modulating gene expression in different tissues, thus, considering gene expression and tissue specificity help clarify common biological mechanisms. We performed TWAS to identify genes whose expression is significantly associated with traits using FUSION²¹. We integrated GWAS summary data with expression weights across 48 tissues from GTEx (Genotype-Tissue Expression, version 7), with one tissue-trait pair at a time. Bonferroni-correction was applied

for all gene-tissue pairs tested (~230,000 in total) within each trait, and $P_{\text{Bonferroni}} < 0.05$ was defined as significance²⁷. To identify an independent set of gene-tissue pairs, we conducted joint/conditional tests (an extension of TWAS) among regions with multiple identified signals³⁷. Shared gene-tissue pairs were determined through intersection across traits.

- 192
- 193 Results

Genome-wide genetic correlation For COVID-19 susceptibility, we found no evidence on a 194 195 shared genetic basis with any of the female-specific cancers (BC: $r_q = -0.01$, P = 0.90; EOC: $r_g = 0.01, P = 0.91; EC: r_g = 0.09, P = 0.23;$ Table 1). For COVID-19 severity, we identified a 196 suggestive genetic correlation for hospitalization with EC ($r_q = 0.19$, P = 0.01), as well as a 197 significant genetic correlation for critical illness with EC ($r_a = 0.29$, $P = 3.00 \times 10^{-4}$). No 198 199 significant result was found for COVID-19 severity with either BC (hospitalization: $r_a = 0.06$, P = 0.16; critical illness: $r_q = 0.05$, P = 0.28) or EOC (hospitalization: $r_q = -0.04$, P = 0.55; 200 critical illness: $r_q = -0.02$, P = 0.77). Interestingly, for EC and COVID-19, both the magnitude 201 202 and the significance of r_q increased as the disease developed, from infection (0.09) to 203 hospitalization (0.19) to critical illness (0.29).

Bidirectional Mendelian randomization We continued to conduct a MR to evaluate potential 204 205 associations of genetically predicted COVID-19 phenotypes on female-specific cancers risk, 206 motivated by the significant shared genetic basis. We identified and selected 16, 38, and 37 207 SNPs as IVs for infection, hospitalization, and critical illness of COVID-19. F-statistics 208 suggested minimal weak instrument bias (Supplementary Table 2). For COVID-19 susceptibility, we did not find any association with female-specific cancer (BC: $OR_{IVW} = 0.99$, 209 95%CI = 0.86-1.14, P = 0.92; EOC: OR_{IVW} = 1.19, 95%CI = 0.95-1.48, P = 0.12; EC: OR_{IVW} = 210 1.26, 95%CI = 0.97-1.64, P = 0.09; Fig 2 and Supplementary Table 3-4). For COVID-19 211 severity, genetically predicted hospitalization ($OR_{IVW} = 1.09, 95\% CI = 1.01 - 1.18, P = 0.04$) and 212 213 critical illness ($OR_{IVW} = 1.06, 95\%CI = 1.00-1.11, P = 0.04$) were associated with the risk of

214 EC under suggestive significance, none of which withstood multiple correction. The estimates remained directionally consistent using the MR-Egger regression (hospitalization: OR = 1.06, 215 95%CI = 0.91-1.24; critical illness: OR = 1.03, 95%CI = 0.93-1.13) or the weighted median 216 217 approach (hospitalization: OR = 1.05, 95% CI = 0.95-1.16; critical illness: OR = 1.03, 95% CI = 218 0.97-1.10). No substantial alteration was found after excluding palindromic SNPs or pleiotropic 219 SNPs, and the leave-one-out analysis demonstrated that the pooled estimate was not driven by 220 any outlying variant. MR-PRESSO yielded to similar findings. No association of genetically 221 predicted COVID-19 severity was found for BC (hospitalization: $OR_{IVW} = 1.00, 95\%$ CI = 0.96-222 1.05; critical illness: $OR_{IVW} = 1.01$, 95% CI = 0.98-1.04) or EOC (hospitalization: $OR_{IVW} = 1.01$, 223 95%CI = 0.92-1.10; critical illness: OR_{IVW} = 0.99, 95%CI = 0.92-1.06).

In the reverse-direction MR where female-specific cancers were considered as exposures, we selected 168, 13, and 16 SNPs as IVs to proxy BC, EOC, and EC. *F*-statistics for these IVs suggested strong instruments (**Supplementary Table 5**). None of the three genetically predicted female-specific cancers appeared to affect COVID-19 susceptibility or severity (**Fig 2** and **Supplementary Table 6**).

229 Cross-trait meta-analysis and pleiotropic loci With little sign of vertical pleiotropy, we continued to perform cross-trait meta-analysis to reveal horizontal pleiotropic effect of 230 individual variant. A total of 20 independent pleiotropic SNPs were identified as shared by BC 231 with at least one COVID-19 phenotype, including 7 for infection, 7 for hospitalization, and 6 232 for critical illness (Fig 3 and Supplementary Table 7-10). These 20 SNPs were mainly located 233 234 at genomic regions 17q21.31 (harboring WNT3, MAPT, CRHR1, and PLEKHM1), 9q34.2 (harboring ABO, LCN1P2, and REXO4), and 1q22 (harboring THBS3, GON4L, and PMF1). 235 Notably, SNP rs910416 located at 6q25.1 showed the most significance ($P_{\text{CPASSOC}} = 1.90 \times 10^{-29}$), 236 followed by SNP rs17474001 at 9q34.2 ($P_{\text{CPASSOC}} = 2.48 \times 10^{-26}$), and SNP rs9411395 at 9q34.2 237 $(P_{\text{CPASSOC}} = 4.71 \times 10^{-26})$. We also identified a novel shared locus (index SNP rs1052067, 238 $P_{\text{CPASSOC}} = 2.76 \times 10^{-08}$) located at 1q22. 239

A total of 15 independent pleiotropic SNPs were identified as shared by EOC with at least one COVID-19 phenotype, including 5 for infection, 6 for hospitalization, and 4 for critical illness. These 15 SNPs were mainly distributed at 2 loci, 9q34.2 (harboring *ABO*, *SURF4*, and *LCN1P2*) and 17q21.31 (harboring *WNT3*, *MAPT*, *CRHR1*, and *PLEKHM1*). All top-three most significant SNPs were located at 9q34.2, including SNP rs554833 ($P_{CPASSOC} = 1.28 \times 10^{-88}$), SNP

- 245 rs657152 ($P_{\text{CPASSOC}} = 6.25 \times 10^{-25}$), and SNP rs56343119 ($P_{\text{CPASSOC}} = 1.28 \times 10^{-22}$).
- A total of 5 independent pleiotropic SNPs were identified as shared by EC with at least one COVID-19 phenotype, including 2 for infection, 3 for hospitalization, and 2 for critical illness. Three out of the 5 shared SNPs were located at 9q34.2 (harboring *ABO*). Among the rest, SNP
- rs1123573 was located at 2p16.1 (harboring BCL11A), and SNP rs17601876 was located at
- 250 15q21.2 (harboring *CYP19A1*, *RP11-108K3*.1). Index SNP rs554833 at 9q34.2 showed the most
- 251 significance ($P_{\text{CPASSOC}} = 3.29 \times 10^{-85}$), followed by SNP rs657152 at 9q34.2 ($P_{\text{CPASSOC}} =$
- 252 3.77×10⁻²⁶), and SNP rs17601876 at 15q21.2 ($P_{\text{CPASSOC}} = 3.07 \times 10^{-14}$).

Identification of causal variants and colocalization For all identified pleiotropic SNPs, we determined a 99% credible set of causal SNPs using FM-summary. A total of 4568 candidate SNPs were identified as the credible set of shared causal SNPs for BC and COVID-19 phenotypes. Corresponding figures in EOC and EC were 4893 and 106. Particularly, we identified only one candidate causal SNP in the 99% credible set for BC/infection (rs12216896), BC/hospitalization (rs2887022), and EC/hospitalization (rs1123573). Lists of candidate causal

259 SNPs at each pleiotropic locus were shown in **Supplementary Table 11-13**.

We next performed colocalization analysis to determine whether genetic variants driving the association between different traits are the same. We identified several loci to colocalize at the same candidate SNPs (PPH4 > 0.5), including 4 shared loci for BC and COVID-19 phenotypes, 8 shared loci for EOC and COVID-19 phenotypes, and 3 shared loci for EC and COVID-19 phenotypes (**Supplementary Table 14**).

Transcriptome-wide association studies and shared genes We identified multiple independent gene-tissue pairs shared between female-specific cancers and COVID-19

267 phenotypes (**Table 2**).

A total of 11 genes were TWAS-significant for BC with at least one COVID-19 phenotype, including 2 with infection, 7 with hospitalization, and 7 with critical illness, enriched in tissues of adrenal gland, artery, brain, heart, pancreas, skin, stomach and whole blood. Two genes were located at pleiotropic loci identified in cross-trait meta-analysis, including *ABO* (enriched in whole blood and shared by BC with all three COVID-19 phenotypes) and *MSTO2P* (enriched in muscle skeletal and pancreas).

A total of 8 genes were TWAS-significant for EOC with at least one COVID-19 phenotype,
including one with infection, 7 with hospitalization, and 6 with critical illness, enriched in
tissues of artery, adrenal gland, brain, breast mammary, pancreas, and vagina. Among these
TWAS significant genes, *ABO* (enriched in artery aorta and shared by EOC with all three
COVID-19 phenotypes), *CRHR1-IT1* (enriched in artery aorta and prostate), and *PLEKHM1*(enriched in brain cortex) were located at pleiotropic loci identified in cross-trait meta-analysis.
Sensitivity analysis for sample overlap A significant genetic correlation between COVID-19

severity and EC as well as a suggestive effect of genetically predicted COVID-19 severity on
EC risk were identified in the main analysis. Given the sample overlap (both GWASs contained
UKB individuals), we additionally conducted a sensitivity analysis applying COVID-19 GWAS

284 excluding UKB subjects. Results of the sensitivity analysis remained consistent with the main

analysis, including directionally consistent genome-wide genetic correlation (infection: $r_a =$

286 0.04, P = 0.59; hospitalization: $r_q = 0.14$, P = 0.03; critical illness: $r_q = 0.22$, $P = 1.70 \times 10^{-3}$),

287 marginal associations between genetically predicted COVID-19 phenotypes with EC risk

288 (infection: $OR_{IVW} = 1.33, 95\%CI = 1.06-1.66$; hospitalization: $OR_{IVW} = 1.11, 95\%CI = 1.03-1.1$;

- critical illness: $OR_{IVW} = 1.06$, 95%CI = 1.00-1.12), as well as 2 replicated pleiotropic SNPs
- 290 (SNP rs1123573 and SNP rs550057, Supplementary Tables 15-18).
- 291

292 Discussion

Leveraging the hitherto largest genetic data and novel statistical approaches, the current study performed a comprehensive genome-wide cross-trait analysis to systematically investigate the shared genetic influences underpinning COVID-19 and female-specific malignancies. Our study covered both the susceptibility and severity of COVID-19, as well as the three most common female cancers, BC, EOC, and EC. From a genetic perspective, our work demonstrated biological links underlying these complex traits, highlighting shared mechanisms rather than potential causal associations.

300 COVID-19 presents a broad spectrum of clinical manifestations ranging from asymptomatic infection to death, with the host genetic determinants one of the main influential factors^{2,38}. For 301 COVID-19 susceptibility, our study suggested no apparent genetic association with any of the 302 303 examined female-specific cancers. While for COVID-19 severity, we found a significant genome-wide genetic correlation for EC with both COVID-19 hospitalization and critical 304 305 illness, highlighting a non-trivial genetic component that is shared by cancer and a worse symptom of COVID-19. Notably, as the severity of infection develops, the overall COVID-19-306 307 EC genetic correlation increases, even with a decreasing sample size of corresponding COVID-308 19 GWAS. This may be explained by a higher level of plasma cytokines and immune responses in severe COVID-19 patients, both of which are well-established hallmarks for cancer 309 initiation^{39,40}. 310

A shared genetic basis can be the result of vertical pleiotropy and/or horizontal pleiotropy. In 311 our downstream analysis performed to explore these alternatives, we identified no association 312 313 of genetically predicted COVID-19 susceptibility with any cancer of interest, largely in line with the overall null genetic correlation. Two previous studies reported suggestive associations 314 between genetically predicted SARS-CoV-2 infection with EC risk (OR = 1.37, 95%CI = 1.11-315 1.69; OR = 1.17, 95%CI = 1.01-1.34)^{41,42}. However, these studies applied a limited number of 316 317 IVs generated from an older version of COVID-19 GWAS (Release 4), which might reduce the precision of MR estimates due to insufficient power. With an eight-times augmented sample 318 size of COVID-19 cases (122,616 vs. 14,134) and a larger number of IVs (16 vs. 3 or 13), our 319

320 MR did not support for such potential associations. For COVID-19 severity, despite suggestive associations identified for genetically predicted hospitalization or critical illness on EC risk, 321 none withstood multiple testing. While these findings were consistent with a previous MR 322 reporting marginal associations (hospitalization: OR = 1.15, 95% CI = 1.00-1.31; critical illness: 323 324 $OR = 1.08, 95\%CI = 1.01-1.15)^{42}$, both the significance and the magnitude of estimates in our study attenuated with a nearly four-times augmented sample size of severe cases 325 326 (hospitalization: 32,519 vs. 6,404; critical illness: 13,769 vs. 4,336) and a five-times enlarged 327 number of IVs (hospitalization: 38 vs. 7; critical illness: 37 vs. 7). Based on our current findings, 328 a worse symptom of COVID-19 does not seem to represent a risk factor for EC development, 329 while future investigations are warranted to further establish or rule out our findings. By 330 applying a reverse directional MR design, we further confirmed that genetically predicted 331 female-specific cancers appear not to affect either the susceptibility or the severity of COVID-19, concordant with a previous MR study 43 . 332

Taken together, our MR analysis delivers timely messages that may have important clinical and 333 334 public health implications. We provide evidence suggesting that COVID-19 is not likely to pose 335 a direct effect on the immediate risk of the examined female-specific cancers, suggesting that extra cancer screening in those recovered from COVID-19 may not confer a substantial public 336 health benefit. In fact, the potential impact of COVID-19 pandemic on routine cancer screening 337 338 should be given attention, which may lead to an increased burden of cancer mortality⁴⁴. 339 Regarding the inconclusive effect of genetically predicted COVID-19 severity on EC risk, the 340 marginal effect size reflects limited clinical significance. Our study, however, has not ruled out the possibility of subsequent increased risks of other chronic diseases, which, like cancer, is 341 crucial for reducing disease burden and promoting health equity in post-COVID era^{4,5}. To 342 343 identify other potential long-term sequelae of COVID-19, cancers in other tissues or of other sites, cardiovascular, hematological, neurological diseases, as well as possible long-term 344 345 chronic inflammation, also require attention.

346 Contrary to the limited genetic evidence observed for vertical pleiotropy, our cross-trait meta-

347 analysis revealed multiple horizontal pleiotropic loci shared between cancers and COVID-19, suggesting that the previously reported phenotypic links could be largely explained by common 348 biological mechanisms. The shared signals identified for both the susceptibility and the severity 349 of COVID-19 further validate the notion that overall genetic correlation may fail to detect 350 351 pleiotropic effects at individual variant level. Notably, many of our identified cross-trait effects were previously implicated in hematologic systems (ABO, THBS3)^{38,45}, immune response 352 (WNT3, PLEKHM1, BCL11A, GON4L)¹², cell proliferation (PMF1, TTC28, KANSL1), and 353 hormone secretion (CRHR1, ESR1, CYP19A1)^{13,14}, reflecting potential mechanistic pathways 354 355 linking COVID-19 to tumorigenesis. Via colocalization analysis, multiple genes (ABO, WNT3, CUX2, SURF4, LCN1P2, CTD-2612A24.1, RP11-430N14.4) showed strong evidence of a 356 357 shared causal mechanism (PPH4 > 0.5). Here we highlight two interesting examples, *ABO* and 358 WNT3, both are shared by COVID-19 with more than one investigated cancer.

ABO, a protein-coding gene involved in blood group systems biosynthesis and coagulation, is 359 a well-known COVID-19 risk gene^{38,46}. In COVID-19 patients, ABO contributes to 360 hypercoagulation states and thromboses by affecting plasma glycoproteins⁴⁶⁻⁴⁹, meanwhile, 361 such hypercoagulation states also frequently occurs in many cancer patients^{50,51}. By regulating 362 the circulating levels of several pro-inflammatory and immune adhesion molecules, ABO might 363 contribute to both tumorigenesis and COVID-19 development^{52,53}. WNT3 represents a typical 364 365 immune-related gene, and was identified as a shared gene for COVID-19 severity (rather than susceptibility) with cancer. By activating the WNT/β-catenin pathway, WNT3 plays a shaping 366 role in tumor proliferation, migration and invasion, and functions in a variety of pathological 367 processes including inflammation, metabolism, neurological development, and fibrosis 368 processes^{54,55}. Demonstrated by previous studies, upregulation of the canonical WNT/ β -catenin 369 pathway in COVID-19 patients is associated with inflammation and cytokine storm⁵⁶, and such 370 inflammatory immune responses are more likely to occur in patients with severe COVID-19^{39,40}. 371 This may explain why immune-related genes such as WNT3 were mainly identified to be shared 372 373 with COVID-19 severity. Our findings suggest critical roles of coagulation and immune

374 responses in both COVID-19 and female-specific cancers regulations, which help pinpoint
 375 therapeutic targets for both diseases.

Integrating GWAS and GTEx tissue-specific expression data, our TWAS analysis further 376 377 revealed biological pleiotropy at a gene-tissue pair level. Similar with findings from CPASSOC, 378 we found shared genes between COVID-19 and cancers that are related to hematologic systems (ABO), immune function (MUC1, PLEKHM1), and cell proliferation (KANSL1-AS1). The 379 380 multiple genes identified in blood vessel or heart tissues indicate a biological mechanism 381 through the cardiovascular system, which corroborates well with the established knowledge as both COVID-19 and cancer are associated with a number of cardiovascular complications^{49,57}. 382 In addition, we identified shared regulatory features in the nervous system, especially for 383 384 COVID-19 severity. In fact, the neuro-invasiveness and neuro-invasion of SARS-CoV-2 have been well-characterized by previous studies, with more than 80% of severe COVID-19 patients 385 showing neurological manifestations during the acute stage of their disease⁵⁸. Through 386 peripheral nerves and/or the hematogenous route, viruses can access the cranial nerves and 387 388 influence disease manifestation⁵⁸. Moreover, the importance of nervous system in cancer 389 development has also been increasingly recognized⁵⁹. Cancer cells transduce neurotransmittermediated intracellular signaling pathways which may lead to their activation, growth, and 390 metastasis⁵⁹. To sum up, these shared biologic pathways for COVID-19 and female-specific 391 392 cancers implicate therapeutic strategies in clinical practice of the coexisting groups. More 393 studies are needed to fully disclose the complex mechanisms.

Several limitations need to be acknowledged. **First,** due to unavailability of data, we conduct our analysis using sex-combined GWAS summary data of COVID-19 which may introduce sex heterogeneity. Future investigations leveraging large-scale sex-specific data may reduce this bias. **Second,** to avoid bias from population stratification, we chose GWAS data restricted to the European ancestry, limiting the generalizability to other ethnic groups. **Third,** the power of our MR analyses could still be limited by sample size, case proportion, and heritability of IVs, leading to the overall negative findings. However, by using data from the hitherto largest GWAS

for COVID-19, our overall statistical power was considerably raised compared with previous genetic studies. We had 80% power at an alpha level of 0.05 to detect a 33% increased cancer risk with infection, a 43% increased risk with hospitalization, and a 47% increased risk with critical illness^{60,61}. Larger GWAS data are needed to validate our results in the future. **Finally,** the delineation of COVID-19 susceptibility and severity phenotypes across studies may have been influenced by local social and medical conditions, introducing heterogeneity in the original meta-GWAS that could not be explained in our analysis.

408

409 Conclusion

410 Overall, our genetic analysis extends previous findings by highlighting an intrinsic link 411 underlying female-specific cancers and COVID-19. COVID-19 is not likely to elevate the 412 immediate risk of female-specific cancers (BC, EOC, EC), but rather appears to share 413 mechanistic pathways with these conditions. Such common biological mechanisms are 414 specifically substantiated by the pleiotropic loci and shared genes identified in our study, 415 implicating therapeutic strategies for future clinical practice.

416

417 **Competing interests**

418 The authors have declared that no competing interests exist.

419

420 Acknowledgments

We thank all the patients, staff and investigators who contributed to the COVID-19 Host Genetics Initiative, BCAC consortium, OCAC consortium and ECAC consortium. This study was supported by funds from the National Natural Science Foundation of China (81874283, 81673255, 81874282), the National Key R&D Program of China (2020YFC2006505), the Health Commission of Sichuan Province (20PJ093), the Key R&D Program of Sichuan, China

426	(2022YFS0055), the Recruitment Program for Young Professionals of China, the Promotion
427	Plan for Basic Medical Sciences, the Development Plan for Cutting-Edge Disciplines, Sichuan
428	University, and other Projects from West China School of Public Health and West China Fourth
429	Hospital, Sichuan University.
430	
431	Data availability
432	This study did not generate new datasets or codes. All data used in our study are publicly-
433	available. GWAS summary statistics of the COVID-19 Host Genetics Initiative are accessible
434	at https://www.covid19hg.org/. GWAS summary statistics for breast cancer, epithelial ovarian
435	cancer, and endometrial cancer can be downloaded from the GWAS catalog
436	(<u>https://www.ebi.ac.uk/gwas/</u>) or from the websites of the consortium
437	(http://bcac.ccge.medschl.cam.ac.uk/bcacdata/, http://ocac.ccge.medschl.cam.ac.uk/). More
438	details of the approaches as well as the codes are available at https://github.com/bulik/ldsc
439	(LDSC), <u>https://mrcieu.github.io/TwoSampleMR/</u> (TwoSampleMR),
440	http://hal.case.edu/~xxz10/zhuweb/ (CPASSOC), https://github.com/hailianghuang/FM-
441	summary (FM-summary), https://chr1swallace.github.io/coloc/ (Coloc), https://www.cog-
442	genomics.org/plink/1.9/ (PLINK), https://grch37.ensembl.org/info/docs/tools/vep/index.html
443	(VEP), http://gusevlab.org/projects/fusion/ (FUSION).

444 **Reference:** 445 Gupta, A. et al. Extrapulmonary manifestations of COVID-19. Nature medicine 26, 1017-1032, 1 446 doi:10.1038/s41591-020-0968-3 (2020). 447 Hu, B., Guo, H., Zhou, P. & Shi, Z. L. Characteristics of SARS-CoV-2 and COVID-19. Nature 2 448 reviews. Microbiology 19, 141-154, doi:10.1038/s41579-020-00459-7 (2021). Brodin, P. Immune determinants of COVID-19 disease presentation and severity. Nature 449 3 450 medicine 27, 28-33, doi:10.1038/s41591-020-01202-8 (2021). 451 4 Sudre, C. H. et al. Attributes and predictors of long COVID. Nature medicine 27, 626-631, 452 doi:10.1038/s41591-021-01292-y (2021). 453 5 Del Rio, C., Collins, L. F. & Malani, P. Long-term Health Consequences of COVID-19. Jama 454 324, 1723-1724, doi:10.1001/jama.2020.19719 (2020). 455 6 Hawkes, S. et al. Recorded but not revealed: exploring the relationship between sex and gender, country income level, and COVID-19. The Lancet. Global health 9, e751-e752, 456 doi:10.1016/s2214-109x(21)00170-4 (2021). 457 Evans, N. G., Berger, Z. D., Phelan, A. L. & Silverman, R. D. Covid-19, equity, and 458 7 459 inclusiveness. BMJ (Clinical research ed.) 373, n1631, doi:10.1136/bmj.n1631 (2021). 460 8 Ball, E., Willmott, F., Rivas, C. & Talati, C. COVID-19 in Women's health: Pre-operative gynaecological assessment and shared decision making. Best practice & research. Clinical 461 obstetrics & gynaecology 73, 12-21, doi:10.1016/j.bpobgyn.2021.03.001 (2021). 462 463 9 Rugge, M., Zorzi, M. & Guzzinati, S. SARS-CoV-2 infection in the Italian Veneto region: 464 adverse outcomes in patients with cancer. Nature cancer 1, 784-788, doi:10.1038/s43018-020-465 0104-9 (2020). 466 10 Lara, O. D. et al. COVID-19 outcomes of patients with gynecologic cancer in New York City: 467 An updated analysis from the initial surge of the pandemic. Gynecologic oncology 164, 304-310, doi:10.1016/j.ygyno.2021.12.004 (2022). 468 469 Li, J. et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical 11 470 characteristics, risk factors, and outcomes. Journal of medical virology 93, 1449-1458, 471 doi:10.1002/jmv.26424 (2021). 472 Zong, Z., Wei, Y., Ren, J., Zhang, L. & Zhou, F. The intersection of COVID-19 and cancer: 12 473 signaling pathways and treatment implications. Molecular cancer 20, 76, doi:10.1186/s12943-474 021-01363-1 (2021). 475 Parmar, H. S. et al. Cross Talk between COVID-19 and Breast Cancer. Current cancer drug 13 targets 21, 575-600, doi:10.2174/1568009621666210216102236 (2021). 476 477 14 Chaudhari, S. et al. Comorbidities and inflammation associated with ovarian cancer and its 478 influence on SARS-CoV-2 infection. Journal of ovarian research 14, 39, doi:10.1186/s13048-479 021-00787-z (2021). 480 Cai, C., Ahmed, O. A., Shen, H. & Zeng, S. Which cancer type has the highest risk of COVID-15 481 19 infection? The Journal of infection 81, 647-679, doi:10.1016/j.jinf.2020.05.028 (2020). 482 16 Saini, G. & Aneja, R. Cancer as a prospective sequela of long COVID-19. BioEssays : news 483 and reviews in molecular, cellular and developmental biology 43. 484 doi:10.1002/bies.202000331 (2021). 485 17 Burgess, S., Scott, R. A., Timpson, N. J., Davey Smith, G. & Thompson, S. G. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. 486 487 European journal of epidemiology 30, 543-552, doi:10.1007/s10654-015-0011-z (2015).

e2000331.

- 488 Zhu, Z., Hasegawa, K., Camargo, C. A., Jr. & Liang, L. Investigating asthma heterogeneity 18 489 through shared and distinct genetics: Insights from genome-wide cross-trait analysis. The 490 Journal of allergy and clinical immunology 147, 796-807, doi:10.1016/j.jaci.2020.07.004 491 (2021).
- 492 Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. Nature 19 493 genetics 47, 1236-1241, doi:10.1038/ng.3406 (2015).
- 494 Zhu, X. et al. Meta-analysis of correlated traits via summary statistics from GWASs with an 20 495 application in hypertension. American journal of human genetics 96, 21-36, 496 doi:10.1016/j.ajhg.2014.11.011 (2015).
- 497 21 Gusev, A. et al. Integrative approaches for large-scale transcriptome-wide association studies. 498 Nature genetics 48, 245-252, doi:10.1038/ng.3506 (2016).
- 499 Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and 22 500 Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians 71, 501 209-249, doi:10.3322/caac.21660 (2021).
- 502 23 Zhang, H. et al. Genome-wide association study identifies 32 novel breast cancer susceptibility 503 and subtype-specific analyses. *Nature genetics* 52, loci from overall 572-581, 504 doi:10.1038/s41588-020-0609-2 (2020).
- 505 24 Phelan, C. M. et al. Identification of 12 new susceptibility loci for different histotypes of 506 epithelial ovarian cancer. Nature genetics 49, 680-691, doi:10.1038/ng.3826 (2017).
- 507 O'Mara, T. A. et al. Identification of nine new susceptibility loci for endometrial cancer. Nature 25 508 communications 9, 3166, doi:10.1038/s41467-018-05427-7 (2018).
- 509 26 The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic 510 factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. European journal of human genetics : EJHG 28, 715-718, doi:10.1038/s41431-020-0636-6 (2020). 511
- 512 27 Bland, J. M. & Altman, D. G. Multiple significance tests: the Bonferroni method. BMJ (Clinical 513 research ed.) 310, 170, doi:10.1136/bmj.310.6973.170 (1995).
- 514 Burgess, S. & Thompson, S. G. Avoiding bias from weak instruments in Mendelian 28 515 randomization studies. International journal of epidemiology **40**. 755-764, 516 doi:10.1093/ije/dyr036 (2011).
- Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: 517 29 518 effect estimation and bias detection through Egger regression. International journal of 519 epidemiology 44, 512-525, doi:10.1093/ije/dyv080 (2015).
- 520 30 Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in Mendelian 521 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genetic 522 epidemiology 40, 304-314, doi:10.1002/gepi.21965 (2016).
- 523 Verbanck, M., Chen, C. Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy 31 524 in causal relationships inferred from Mendelian randomization between complex traits and 525 diseases. Nature genetics 50, 693-698, doi:10.1038/s41588-018-0099-7 (2018).
- 526 Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage 32 527 analyses. American journal of human genetics 81, 559-575, doi:10.1086/519795 (2007).
- 528 33 Howe, K. L. et al. Ensembl 2021. Nucleic acids research 49, D884-d891, 529 doi:10.1093/nar/gkaa942 (2021).
- 530 Schaid, D. J., Chen, W. & Larson, N. B. From genome-wide associations to candidate causal 34 531 variants by statistical fine-mapping. Nature reviews. Genetics 19, 491-504, doi:10.1038/s41576-

532		018-0016-z (2018).
533	35	Farh, K. K. et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants.
534		Nature 518, 337-343, doi:10.1038/nature13835 (2015).
535	36	Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association
536		studies using summary statistics. PLoS genetics 10, e1004383,
537		doi:10.1371/journal.pgen.1004383 (2014).
538	37	Gusev, A. et al. Transcriptome-wide association study of schizophrenia and chromatin activity
539		yields mechanistic disease insights. Nature genetics 50, 538-548, doi:10.1038/s41588-018-
540		0092-1 (2018).
541	38	Mapping the human genetic architecture of COVID-19. Nature 600, 472-477,
542		doi:10.1038/s41586-021-03767-x (2021).
543	39	Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2
544		pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet.
545		Respiratory medicine 8, 475-481, doi:10.1016/s2213-2600(20)30079-5 (2020).
546	40	Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
547		China. Lancet (London, England) 395, 497-506, doi:10.1016/s0140-6736(20)30183-5 (2020).
548	41	Gao, R. et al. Genetic variation associated with COVID-19 is also associated with endometrial
549		cancer. The Journal of infection 84, e85-e86, doi:10.1016/j.jinf.2022.01.026 (2022).
550	42	Wu, X. et al. Novel evidence revealed genetic association between COVID-19 infection,
551		severity and endometrial cancer. The Journal of infection 85, e1-e3,
552		doi:10.1016/j.jinf.2022.05.005 (2022).
553	43	Li, Z., Wei, Y., Zhu, G., Wang, M. & Zhang, L. Cancers and COVID-19 Risk: A Mendelian
554		Randomization Study. Cancers 14, doi:10.3390/cancers14092086 (2022).
555	44	Janda, M., Paul, C. & Horsham, C. Changes in cancer preventive behaviours, screening and
556		diagnosis during COVID-19. Psycho-oncology 30, 271-273, doi:10.1002/pon.5575 (2021).
557	45	Zhang, C. et al. The Integrative Analysis of Thrombospondin Family Genes in Pan-Cancer
558		Reveals that THBS2 Facilitates Gastrointestinal Cancer Metastasis. Journal of oncology 2021,
559		4405491, doi:10.1155/2021/4405491 (2021).
560	46	Hernández Cordero, A. I. et al. Multi-omics highlights ABO plasma protein as a causal risk
561		factor for COVID-19. Human genetics 140, 969-979, doi:10.1007/s00439-021-02264-5 (2021).
562	47	Matsui, T., Titani, K. & Mizuochi, T. Structures of the asparagine-linked oligosaccharide chains
563		of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. The
564		Journal of biological chemistry 267 , 8723-8731 (1992).
565	48	Teuwen, L. A., Geldhof, V., Pasut, A. & Carmeliet, P. COVID-19: the vasculature unleashed.
566		Nature reviews. Immunology 20, 389-391, doi:10.1038/s41577-020-0343-0 (2020).
567	49	Franchini, M., Favaloro, E. J., Targher, G. & Lippi, G. ABO blood group, hypercoagulability,
568		and cardiovascular and cancer risk. Critical reviews in clinical laboratory sciences 49, 137-149,
569		doi:10.3109/10408363.2012.708647 (2012).
570	50	Falanga, A., Marchetti, M. & Vignoli, A. Coagulation and cancer: biological and clinical aspects.
571		Journal of thrombosis and haemostasis : JTH 11, 223-233, doi:10.1111/jth.12075 (2013).
572	51	Rodrigues, C. A., Ferrarotto, R., Kalil Filho, R., Novis, Y. A. & Hoff, P. M. Venous
573		thromboembolism and cancer: a systematic review. Journal of thrombosis and thrombolysis 30,
574		67-78, doi:10.1007/s11239-010-0441-0 (2010).
575	52	Barbalic, M. et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and

576		sICAM-1 levels. Human molecular genetics 19, 1863-1872, doi:10.1093/hmg/ddq061 (2010).
577	53	Paterson, A. D. et al. Genome-wide association identifies the ABO blood group as a major locus
578		associated with serum levels of soluble E-selectin. Arteriosclerosis, thrombosis, and vascular
579		biology 29, 1958-1967, doi:10.1161/atvbaha.109.192971 (2009).
580	54	Grainger, S. & Willert, K. Mechanisms of Wnt signaling and control. Wiley interdisciplinary
581		reviews. Systems biology and medicine, e1422, doi:10.1002/wsbm.1422 (2018).
582	55	Liu, J. et al. Wnt/\beta-catenin signalling: function, biological mechanisms, and therapeutic
583		opportunities. Signal transduction and targeted therapy 7, 3, doi:10.1038/s41392-021-00762-6
584		(2022).
585	56	Vallée, A., Lecarpentier, Y. & Vallée, J. N. Interplay of Opposing Effects of the WNT/β-Catenin
586		Pathway and PPARy and Implications for SARS-CoV2 Treatment. Frontiers in immunology 12,
587		666693, doi:10.3389/fimmu.2021.666693 (2021).
588	57	Roh, J. D. et al. Plasma Proteomics of COVID-19-Associated Cardiovascular Complications:
589		Implications for Pathophysiology and Therapeutics. JACC. Basic to translational science 7,
590		425-441, doi:10.1016/j.jacbts.2022.01.013 (2022).
591	58	Bauer, L. et al. The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2.
592		Trends in neurosciences 45, 358-368, doi:10.1016/j.tins.2022.02.006 (2022).
593	59	Kuol, N., Stojanovska, L., Apostolopoulos, V. & Nurgali, K. Role of the nervous system in
594		cancer metastasis. Journal of experimental & clinical cancer research : CR 37, 5,
595		doi:10.1186/s13046-018-0674-x (2018).
596	60	Shim, H. et al. A multivariate genome-wide association analysis of 10 LDL subfractions, and
597		their response to statin treatment, in 1868 Caucasians. PloS one 10, e0120758,
598		doi:10.1371/journal.pone.0120758 (2015).
599	61	Brion, M. J., Shakhbazov, K. & Visscher, P. M. Calculating statistical power in Mendelian
600		randomization studies. International journal of epidemiology 42, 1497-1501,
601		doi:10.1093/ije/dyt179 (2013).
602		



603

604 Fig 1. Overall study design of genome-wide cross-trait analysis. GWAS summary statistics

605 for each trait of interest were retrieved from publicly available GWAS(s). GWAS: genome-

606 wide association study; UKB: UK Biobank.

Cancer	COVID-19 phenotype	r_g	95%CI	<i>P</i> -value
	Infection	-0.01	(-0.09,0.08)	0.90
BC	Hospitalization	0.06	(-0.02,0.14)	0.16
	Critical illness	0.05	(-0.04,0.13)	0.28
	Infection	0.01	(-0.16,0.18)	0.91
EOC	Hospitalization	-0.04	(-0.19,0.10)	0.55
	Critical illness	-0.02	(-0.17,0.13)	0.77
	Infection	0.09	(-0.06,0.24)	0.23
EC	Hospitalization	0.19	(0.04,0.34)	0.01
	Critical illness	0.29	(0.14,0.45)	3.00×10 ⁻⁴ *

Table	1.	Genetic	correlation	between	female-specific	cancers	and	COVID-19
phenot	type	es.						

Bold-face: P < 0.05; * $P < 5.56 \times 10^{-3}$.

 r_g : genetic correlation; CI: confidence interval; Infection: reported SARS-CoV-2 infection vs. population; Hospitalization: COVID-19 hospitalization patients vs. population; Critical illness: very severe respiratory confirmed COVID-19 patients vs. population; BC: breast cancer; EOC: overall invasive epithelial ovarian cancer; EC: endometrial cancer

		Outcom	e: female−specific	cancer		c)utcome: COVID-19	
	No. SNPs	OR(95%CI)		P-value	No. SNPs	OR(95%CI)		P-value
Breast cancer								
Infection	16	0.99 (0.86-1.14)	⊢ ∎1	0.92	165	1.00 (0.99-1.02)	H I	0.71
Hospitalization	37	1.00 (0.96-1.05)	HEH	0.86	154	1.01 (0.97-1.04)	H=H	0.69
Critical illness	36	1.01 (0.98-1.04)	Hend	0.56	153	1.00 (0.94-1.05)	┝╼┲╌┥	0.87
Epithelial ovarian	cancer							
Infection	16	1.19 (0.95-1.48)	F ■ 1	0.12	13	1.02 (0.92-1.13)	⊢ ∎i	0.71
Hospitalization	37	1.01 (0.92-1.10)	⊢∎→	0.89	13	0.98 (0.84-1.15)	←	0.84
Critical illness	36	0.99 (0.92-1.06)	⊢∎⊣	0.69	13	1.00 (0.81-1.24)	← – – – – – – – – – – – – – – – – – – –	0.97
Endometrial canc	er							
Infection	16	1.26 (0.97-1.64)	⊢	• 0.09	15	0.99 (0.96-1.03)	H a -1	0.68
Hospitalization	36	1.09 (1.01–1.18)	⊢ ∎-4	0.04	15	0.99 (0.92-1.07)	⊢	0.78
Critical illness	35	1.06 (1.00-1.11)		0.04 1	15	1.07 (0.98-1.17)		0.13
		0.	75 1 1.25 1 Odds Ratio (95%CI)	.5		0	.85 1 1.2 Odds Ratio (95%CI)	25

609

Fig 2. Bidirectional Mendelian randomization associations between COVID-19 610

611 phenotypes and female-specific cancers. On the left are the MR effect estimates of

genetically predicted COVID-19 phenotypes on each female-specific cancer by the inverse-612

613 variance weighted approach. On the right are the MR effect estimates of genetically predicted

female-specific cancer on COVID-19 phenotypes by the inverse-variance weighted approach. 614

Boxes represent the point estimates of MR effects, and error bars represent 95% confidence 615

616 intervals.

617





Fig 3. Pleiotropic loci between female-specific cancers and COVID-19 phenotypes identified from cross-trait meta-analysis. (A) Pleiotropic loci identified for breast cancer and COVID-19 phenotypes; (B) pleiotropic loci identified for epithelial ovarian cancer and COVID-19 phenotypes; (C) pleiotropic loci identified for endometrial cancer and COVID-19 phenotypes. In each circular Manhattan plot, the circle from center to periphery shows the cross-trait meta-analysis results between each female-specific cancer and the three COVID-19 phenotypes (light blue: SRAS-CoV-2 infection, blue: COVID-19 hospitalization, dark blue: COVID-19 critical illness). The outermost numbers represent chromosomes 1-22. The red dots represent significant pleiotropic SNPs in cross-trait meta-analysis ($P_{CPASSOC} < 5 \times 10^{-8}$ and $P_{single-trait} < 1 \times 10^{-3}$ in both traits).

			No		Female-spec	ific can	cer	COVID-19				
Gene	Tissue Type	CHR	INO. SNPs	Туре	BEST. GWAS.ID	Z	P _{Bonferroni}	Subtype	BEST. GWAS.ID	Z	P _{Bonferroni}	
Breast cancer ar	nd COVID-19											
GBAP1	Adrenal Gland	1	328	BC	rs4971059	-6.73	3.89×10 ⁻⁶	Infection	rs11264339	7.05	4.06×10 ⁻⁷	
GBAP1	Artery Aorta	1	328	BC	rs4971059	-6.49	1.96×10 ⁻⁵	Infection	rs11264339	7.24	1.04×10 ⁻⁷	
GBAP1	Artery Coronary	1	328	BC	rs4971059	-5.68	3.10×10 ⁻³	Infection	rs11264339	7.09	3.02×10 ⁻⁷	
GBAP1	Artery Tibial	1	328	BC	rs4971059	-6.30	7.05×10 ⁻⁵	Infection	rs11264339	6.97	7.24×10 ⁻⁷	
GBAP1	Cells Transformed fibroblasts	1	328	BC	rs4971059	-6.44	2.72×10 ⁻⁵	Infection	rs11264339	7.13	2.34×10 ⁻⁷	
GBAP1	Esophagus Muscularis	1	328	BC	rs4971059	-6.71	4.68×10-6	Infection	rs11264339	6.80	2.39×10^{-6}	
GBAP1	Heart Atrial Appendage	1	328	BC	rs4971059	-5.68	3.10×10^{-3}	Infection	rs11264339	7.09	3.02×10^{-7}	
GBAP1	Skin Not Sun Exposed Suprapubic	1	328	BC	rs4971059	-6.84	1.79×10 ⁻⁶	Infection	rs11264339	7.00	5.92×10 ⁻⁷	
GBAP1	Skin Sun Exposed Lower leg	1	328	BC	rs4971059	-6.62	8.19×10 ⁻⁶	Infection	rs11264339	7.05	4.04×10 ⁻⁷	
ABO	Whole Blood	9	595	BC	rs495828	-5.34	2.15×10^{-2}	Infection	rs612169	-10.05	2.24×10^{-18}	
KANSL1-AS1	Artery Coronary	17	29	BC	rs17763086	-6.03	3.93×10 ⁻⁴	Hospitalization	rs8072451	-7.57	8.91×10 ⁻⁹	
KANSL1-AS1	Brain Anterior cingulate cortex BA24	17	29	BC	rs17763086	-6.03	3.93×10 ⁻⁴	Hospitalization	rs8072451	-7.57	8.91×10 ⁻⁹	
RP11-259G18.1	Brain Cortex	17	66	BC	rs17763086	-6.03	3.93×10 ⁻⁴	Hospitalization	rs8072451	-7.57	8.91×10 ⁻⁹	
CRHR1-IT1	Stomach	17	93	BC	rs17763086	-6.03	3.93×10 ⁻⁴	Hospitalization	rs8072451	-7.57	8.91×10 ⁻⁹	
RPS26P8	Pituitary	17	106	BC	rs17763086	-6.03	3.93×10 ⁻⁴	Hospitalization	rs8072451	-7.57	8.91×10 ⁻⁹	
RP11-707O23.5	Artery Tibial	17	111	BC	rs17763086	-6.15	1.77×10 ⁻⁴	Hospitalization	rs8072451	-7.87	7.98×10 ⁻¹⁰	
RP11-707O23.5	Brain Hypothalamus	17	111	BC	rs17763086	-6.03	3.72×10 ⁻⁴	Hospitalization	rs8072451	-7.58	7.84×10 ⁻⁹	
LRRC37A4P	Adrenal Gland	17	138	BC	rs17763086	6.03	3.93×10 ⁻⁴	Hospitalization	rs8072451	7.57	8.91×10 ⁻⁹	
LRRC37A4P	Heart Left Ventricle	17	138	BC	rs17763086	6.07	3.05×10 ⁻⁴	Hospitalization	rs8072451	7.65	4.79×10 ⁻⁹	
ABO	Whole Blood	9	595	BC	rs495828	-5.34	2.15×10 ⁻²	Hospitalization	rs657152	-5.70	2.80×10-3	
RP11-707O23.5	Artery Tibial	17	111	BC	rs17763086	-6.15	1.77×10 ⁻⁴	Critical illness	rs16940665	-7.59	7.13×10 ⁻⁹	
RP11-707O23.5	Brain Hypothalamus	17	111	BC	rs17763086	-6.03	3.72×10 ⁻⁴	Critical illness	rs16940665	-7.40	3.10×10 ⁻⁸	
LRRC37A4P	Brain Nucleus accumbens basal ganglia	17	138	BC	rs17763086	6.03	3.82×10 ⁻⁴	Critical illness	rs16940665	7.45	2.13×10 ⁻⁸	
MSTO2P	Muscle Skeletal	1	236	BC	rs11264372	-6.45	2.65×10 ⁻⁵	Critical illness	rs11803917	-5.70	2.73×10 ⁻³	
MSTO2P	Pancreas	1	236	BC	rs11264372	-6.28	7.94×10 ⁻⁵	Critical illness	rs11803917	-5.43	1.32×10 ⁻²	
HCN3	Brain Nucleus accumbens basal ganglia	1	298	BC	rs4971059	-7.75	2.13×10-9	Critical illness	rs35154152	-5.38	1.73×10 ⁻²	
GBAP1	Brain Cerebellum	1	328	BC	rs4971059	-7.01	5.75×10 ⁻⁷	Critical illness	rs35154152	-5.44	1.23×10 ⁻²	

able 2. I w AS-identified shared gene-tissue pairs between COVID-19 and female-specific cancers after conditional and join	nt analys	oint.	ioir	nd	l a	nal	tior	liti	ondi	con	ter	s afte	cers	canc	ic (ecifi	-spe	ale	ema	d fi	and	-19	'ID-	OV	n (een	etw	s be	airs	na	issue	ne-i	ger	ired	sha	ed s	tifie	iden	S-i	NA	T	e 2.	abl	T
--	-----------	-------	------	----	-----	-----	------	------	------	-----	-----	--------	------	------	------	-------	------	-----	-----	------	-----	-----	------	----	-----	-----	-----	------	------	----	-------	------	-----	------	-----	------	-------	------	-----	----	---	------	-----	---

MUC1	Pancreas	1	339	BC	rs4971059	6.47	2.24×10 ⁻⁵	Critical illness	rs35154152	5.25	3.59×10 ⁻²
ABO	Whole Blood	9	595	BC	rs495828	-5.34	2.15×10 ⁻²	Critical illness	rs657152	-5.57	5.98×10 ⁻³
Epithelial ovaria	n cancer and COVID-19										
ABO	Artery Aorta	9	595	EOC	rs495828	5.60	4.92×10-3	Infection	rs612169	17.33	6.75×10 ⁻⁶²
KANSL1-AS1	Brain Anterior cingulate cortex BA24	17	29	EOC	rs4566211	7.08	3.35×10 ⁻⁷	Hospitalization	rs8072451	-7.57	8.91×10 ⁻⁹
KANSL1-AS1	Vagina	17	29	EOC	rs4566211	7.10	2.87×10-7	Hospitalization	rs8072451	-7.54	1.05×10 ⁻⁸
RP11-259G18.2	Small Intestine Terminal Ileum	17	59	EOC	rs4566211	7.16	1.82×10 ⁻⁷	Hospitalization	rs8072451	-7.58	7.80×10-9
CRHR1-IT1	Artery Aorta	17	93	EOC	rs17631676	7.11	2.66×10 ⁻⁷	Hospitalization	rs8072451	-7.55	9.99×10 ⁻⁹
CRHR1-IT1	Prostate	17	93	EOC	rs17631676	7.10	2.87×10 ⁻⁷	Hospitalization	rs8072451	-7.54	1.05×10 ⁻⁸
RPS26P8	Breast Mammary Tissue	17	106	EOC	rs17631676	7.08	3.35×10 ⁻⁷	Hospitalization	rs8072451	-7.57	8.91×10 ⁻⁹
RPS26P8	Pituitary	17	106	EOC	rs17631676	7.08	3.35×10 ⁻⁷	Hospitalization	rs8072451	-7.57	8.91×10 ⁻⁹
LRRC37A4P	Adrenal Gland	17	138	EOC	rs17631676	-7.08	3.35×10 ⁻⁷	Hospitalization	rs8072451	7.57	8.91×10 ⁻⁹
PLEKHM1	Brain Cortex	17	162	EOC	rs17631676	7.25	9.99×10 ⁻⁸	Hospitalization	rs8072451	-5.19	5.00×10 ⁻²
ABO	Artery Aorta	9	595	EOC	rs495828	5.60	4.92×10 ⁻³	Hospitalization	rs657152	8.79	3.49×10 ⁻¹³
KANSL1-AS1	Pancreas	17	29	EOC	rs4566211	7.12	2.61×10 ⁻⁷	Critical illness	rs16940665	-7.42	2.83×10 ⁻⁸
KANSL1-AS1	Vagina	17	29	EOC	rs4566211	7.10	2.87×10-7	Critical illness	rs16940665	-7.45	2.18×10-8
RP11-259G18.2	Small Intestine Terminal Ileum	17	59	EOC	rs4566211	7.16	1.82×10 ⁻⁷	Critical illness	rs16940665	-7.52	1.29×10 ⁻⁸
RP11-259G18.1	Brain Hippocampus	17	65	EOC	rs4566211	7.11	2.66×10-7	Critical illness	rs16940665	-7.46	1.94×10 ⁻⁸
CRHR1-IT1	Artery Aorta	17	93	EOC	rs17631676	7.11	2.66×10 ⁻⁷	Critical illness	rs16940665	-7.46	1.94×10 ⁻⁸
LRRC37A4P	Brain Amygdala	17	137	EOC	rs17631676	-7.11	2.66×10 ⁻⁷	Critical illness	rs16940665	7.46	1.94×10 ⁻⁸
ABO	Artery Aorta	9	595	EOC	rs495828	5.60	4.92×10 ⁻³	Critical illness	rs657152	6.68	5.70×10 ⁻⁶

Infection: reported SARS-CoV-2 infection vs. population; Hospitalization: hospitalized COVID-19 patients vs. population; Critical illness: very severe respiratory confirmed COVID-19 patients vs. population; BC: breast cancer; EOC: overall invasive epithelial ovarian cancer; TWAS: transcriptome-wide association study; GWAS: genome-wide association study; SNP: single nucleotide polymorphism; CHR: Chromosome; ID: identifier; No. SNPs: number of SNPs in the locus; Z: Z value for TWAS.